Back

Dysfunctional high-density lipoproteins in breast cancer patients and tumor-bearing mice treated with chemotherapy

29 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Special populations in cardio-oncology Cancer Biology and Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Sandrine Lecour

University of Cape Town, Cape Town (South Africa)

8 More presentations in this session

Presentation thumbnail
Valvular heart disease in Cancer patiEntS - prevAlence, Relevance, and therapeutic management - preliminary results from the CESAR study
Doctor L. Hauptmann (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Low cardiovascular event rates in patients treated with CAR T-cells: real-world outcomes from two independent cohorts
Mr J. Voran (Kiel, DE)
Abstract Slides Video
Presentation thumbnail
Novel biomarker-based machine learning model in personalized cardiotoxicity prediction.
Ms I. Liu (Austin, US)
Abstract Slides Video
Presentation thumbnail
The incidence and risk factors for early onset atrial fibrillation in allogeneic and autologous hematopoietic stem cell transplant patients
Ms L. Cai (Duarte, US)
Abstract Slides Video
Presentation thumbnail
Clinical and echocardiographic characteristics of neuroendocrine tumours and carcinoid heart disease: insights from a contemporary canadian cohort study
Mr J. Yoon (Vancouver, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Special populations in cardio-oncology

The Event

Event poster

ESC Congress 2025

29 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Chemotherapy versus tumour burden: evaluating their roles in cardiovascular risk enhancement for breast cancer patients
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
thumbnail
Congress Presentation
MyD-88/NLRP-3 inhibition by dapagliflozin protects against anthracycline and trastuzumab cardiotoxicity in preclinical models

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources